why choose us

First received: November 29, 2023

Clinical Trial: Phase I Study of ANK-101 in Advanced Tumors

Study Status: Completed

Recruit Status: RECRUITING

Condition: Advanced Solid Tumor

Study Type: INTERVENTIONAL


Official Title: A Phase I Open-Label, Dose Escalation Study of the Safety and Tolerability of ANK-101 in Advanced Cutaneous, Subcutaneous, Soft Tissue or Nodal Tumors

Brief Summary: This is a Phase 1, multicenter, open-label dose escalation study to determine the safety and tolerability of intratumoral (IT) injection of ANK-101 in participants with advanced solid tumors.

Read more